异基因造血干细胞移植时代的急性肾损伤
该单中心回顾性研究纳入2014–2017年616例异基因造血干细胞移植受者,按KDIGO标准定义AKI和CKD。第100天AKI发生率为64%,他克莫司等肾毒性药物暴露增加AKI风险,但他克莫司血药浓度与严重程度无关;AKI患者非复发死亡率更高(HR 2.77,95%CI 1.8–4.27)。
要点
- 异基因造血干细胞移植后第100天AKI发生率高达64%。
- 他克莫司等肾毒性药物暴露增加AKI风险,但血药浓度与严重程度无关。
- AKI患者非复发死亡风险显著升高(HR 2.77,95%CI 1.8–4.27)。
核心结论
- 异基因造血干细胞移植后AKI仍是主要并发症,与更高的非复发死亡率相关(HR 2.77,95%CI 1.8–4.27)。
研究设计与样本
- 单中心回顾性研究,纳入2014–2017年616例异基因造血干细胞移植受者,按KDIGO标准定义AKI和CKD。
主要发现
- 第100天AKI发生率为64%。
- 他克莫司等肾毒性药物暴露与更高AKI风险相关,但他克莫司血药浓度与AKI严重程度无关。
- 降低强度预处理较清髓性预处理AKI风险更高。
- 616例中21例(3%)启动肾脏替代治疗,其中9例(43%)肾功能恢复,5例(24%)存活至出院。
- T细胞清除移植、较高基线血清白蛋白及非西班牙裔与较低AKI风险相关。
关键数值与推荐
- AKI和CKD依据KDIGO标准定义,eGFR采用CKD-EPI方程估算。
- 12个月后21%(73/345)患者发生CKD。
临床怎么用
- 移植后应密切监测AKI,尤其使用他克莫司等肾毒性药物者。
- T细胞清除移植和较高基线血清白蛋白与较低AKI风险相关,可作为风险分层参考。
局限性
- 单中心回顾性设计,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: AKI is a major complication of allogeneic hematopoietic stem cell transplantation, increasing risk of nonrelapse mortality. AKI etiology is often ambiguous due to heterogeneity of conditioning/graft versus host disease regimens. To date, graft versus host disease and calcineurin inhibitor effects on AKI are not well defined. We aimed to describe AKI and assess pre-/post-hematopoietic transplant risk factors in a large recent cohort. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a single-center, retrospective study of 616 allogeneic hematopoietic cell transplant recipients from 2014 to 2017. We defined AKI and CKD based on Kidney Disease Improving Global Outcomes (KDIGO) criteria and estimated GFR using the Chronic Kidney Disease Epidemiology Collaboration equation. We assessed AKI pre-/post-hematopoietic transplant risk factors using cause-specific Cox regression and association of AKI with CKD outcomes using chi-squared test. AKI was treated as a time-dependent variable in relation to nonrelapse mortality. RESULTS: Incidence of AKI by day 100 was 64%. Exposure to tacrolimus and other nephrotoxins conferred a higher risk of AKI, but tacrolimus levels were not associated with severity. Reduced-intensity conditioning carried higher AKI risk compared with myeloablative conditioning. Most stage 3 AKIs were due to ischemic acute tubular necrosis and calcineurin inhibitor nephrotoxicity. KRT was initiated in 21 out of 616 patients (3%); of these 21 patients, nine (43%) recovered and five (24%) survived to hospital discharge. T cell-depleted transplants, higher baseline serum albumin, and non-Hispanic ethnicity were associated with lower risk of AKI. CKD developed in 21% (73 of 345) of patients after 12 months. Nonrelapse mortality was higher in those with AKI (hazard ratio, 2.77; 95% confidence interval, 1.8 to 4.27). CONCLUSIONS: AKI post-hematopoietic cell transplant remains a major concern. Risk of AKI was higher with exposure to calcineurin inhibitors. T cell-depleted hematopoietic cell transplants and higher serum albumin had lower risk of AKI. Of the patients requiring KRT, 43% recovered kidney function. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_09_07_CJN19801220.mp3.
引用
- Abramson MH, Gutgarts V, Zheng J, et al. Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation. Clin J Am Soc Nephrol. 2021. PMID: 34135023. doi:10.2215/CJN.19801220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。